Skip to main content

Advertisement

SpringerLink
Log in

HCV: Fibrosis Progression

  • Hepatitis C (M Bourlière and T Asselah, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Chronic hepatitis C is a frequent disease worldwide and is responsible for a high rate of advanced fibrosis and a significant risk of liver complications and death in patients. Liver fibrosis progression illustrates the aggravation of the disease and the increasing risks over time. Many tools are available to diagnose fibrosis progression, and recent results display how in 2014 liver biopsy is avoidable for patient monitoring and prognosis prediction. Many host and viral factors are associated with fibrosis progression, and more data are now available on the impact of antiviral treatment and sustained virological response on liver fibrosis, whatever its severity, and long-term patient’s outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet. 2003;362:2095–100.

    Article  CAS  PubMed  Google Scholar 

  2. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414–26.

    Article  CAS  PubMed  Google Scholar 

  3. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–13.

    Article  CAS  PubMed  Google Scholar 

  4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.

    Article  CAS  PubMed  Google Scholar 

  5. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.

    Article  CAS  PubMed  Google Scholar 

  6. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.

    Article  CAS  PubMed  Google Scholar 

  7. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.

    Article  CAS  PubMed  Google Scholar 

  8. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–8.

    Article  PubMed  Google Scholar 

  9. Hoofnagle JH, Sherker AH. Therapy for hepatitis C—the costs of success. N Engl J Med. 2014;370:1552–3.

    Article  CAS  PubMed  Google Scholar 

  10. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatol. 2008;48:418–31.

    Article  Google Scholar 

  11. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol. 1997;112:463–72.

    Article  CAS  Google Scholar 

  12. Lok AS, Everhart JE, Wright EC, et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterol. 2010;140:840–9. quiz e12.

    Article  Google Scholar 

  13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatol. 1996;24:289–93.

    Article  CAS  Google Scholar 

  14. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.

    Article  CAS  PubMed  Google Scholar 

  15. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182:1595–601.

    Article  CAS  PubMed  Google Scholar 

  16. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatol. 2003;38:1449–57.

    Article  Google Scholar 

  17. Boursier J, Brochard C, Bertrais S, et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40:178–88. The first large study to present the prognostic value of noninvasive blood scores of fibrosis in chronic hepatitis C.

    Article  CAS  PubMed  Google Scholar 

  18. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterol. 2011;140:1970–9. The first large study to present the prognostic value of liver stiffness measurement in chronic hepatitis C.

    Article  Google Scholar 

  19. Fernandez-Montero JV, Barreiro P, Vispo E, et al. Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. AIDS. 2013;27:1129–34.

    Article  CAS  PubMed  Google Scholar 

  20. Vergniol J, Boursier J, Coutzac C, et al. The evolution of non-invasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatol. 2014;60(1):65–76. The first study evaluating the impact on survival of SVR and the evolution of liver stiffness and noninvasive blood tests in HCV patients.

    Article  Google Scholar 

  21. Hu SX, Kyulo NL, Xia VW, et al. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol. 2009;43:758–64.

    Article  CAS  PubMed  Google Scholar 

  22. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9945):766–81.

    Article  PubMed  Google Scholar 

  23. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterol. 2003;125:1695–704.

    Article  CAS  Google Scholar 

  24. Hull MW, Rollet K, Moodie EE, et al. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS. 2012;26:1789–94.

    Article  CAS  PubMed  Google Scholar 

  25. Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med. 2001;134:120–4.

    Article  CAS  PubMed  Google Scholar 

  26. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatol. 1998;28:805–9.

    Article  CAS  Google Scholar 

  27. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatol. 1998;27:914–9.

    Article  CAS  Google Scholar 

  28. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6:69–75.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Hezode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterol. 2008;134:432–9.

    Article  Google Scholar 

  30. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatol. 2005;42:63–71.

    Article  CAS  Google Scholar 

  31. Brunet L, Moodie EE, Rollet K, et al. Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis. 2013;57:663–70.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Baur K, Mertens JC, Schmitt J, et al. Combined effect of 25-OH vitamin D plasma levels and genetic vitamin D receptor (NR 1I1) variants on fibrosis progression rate in HCV patients. Liver Int. 2011;32:635–43.

    Article  PubMed  Google Scholar 

  33. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatol. 2007;46:297–306.

    Article  CAS  Google Scholar 

  34. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatol. 2009;50:1038–44.

    Article  CAS  Google Scholar 

  35. Patin E, Kutalik Z, Guergnon J, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterol. 2012;143:1244–52. e1-12.

    Article  CAS  Google Scholar 

  36. Noureddin M, Wright EC, Alter HJ, et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatol. 2013;58:1548–57.

    Article  CAS  Google Scholar 

  37. Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–65.

    Article  CAS  PubMed  Google Scholar 

  38. Mandorfer M, Payer BA, Schwabl P, et al. Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int 2014.

  39. Konerman MA, Mehta SH, Sutcliffe CG, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatol. 2014;59:767–75.

    Article  CAS  Google Scholar 

  40. Sanmartin R, Tor J, Sanvisens A, et al. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline. HIV Med. 2013;15:203–12.

    Article  PubMed  Google Scholar 

  41. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatol. 2000;32:1106–10.

    Article  CAS  Google Scholar 

  42. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938–45.

    Article  PubMed  Google Scholar 

  43. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005;42:799–805.

    Article  CAS  PubMed  Google Scholar 

  44. Masuzaki R, Tateishi R, Yoshida H, et al. Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography. World J Gastroenterol. 2012;18:1385–90.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Delladetsima I, Psichogiou M, Sypsa V, et al. Time of acquisition of HCV infection in renal transplant recipients: a major prognostic factor for disease progression. Clin Transplant. 2012;27:72–9.

    Article  PubMed  Google Scholar 

  46. Cross TJ, Quaglia A, Hughes S, et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16:492–9.

    Article  CAS  PubMed  Google Scholar 

  47. Lok AS, Everhart JE, Chung RT, et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatol. 2009;49:1828–37.

    Article  CAS  Google Scholar 

  48. Morishima C, Shiffman ML, Dienstag JL, et al. Reduction in hepatic inflammation is associated with less fibrosis progression and fewer clinical outcomes in advanced hepatitis C. Am J Gastroenterol 2012.

  49. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterol. 2003;124:97–104.

    Article  Google Scholar 

  50. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatol. 1996;23:1334–40.

    Article  CAS  Google Scholar 

  51. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu. 1979;14(Pt 2):183–213.

    PubMed  Google Scholar 

  52. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatol. 2004;39:333–42.

    Article  CAS  Google Scholar 

  53. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterol. 2002;122:1303–13. The first large study evaluating fibrosis regression in SVR patients.

    Article  CAS  Google Scholar 

  54. Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatol. 2011;54:1547–58.

    Article  Google Scholar 

  55. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatol. 1997;26:780–5.

    Article  CAS  Google Scholar 

  56. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–65.

    Article  CAS  PubMed  Google Scholar 

  57. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis interventional therapy group. N Engl J Med. 1998;339:1485–92.

    Article  CAS  PubMed  Google Scholar 

  58. Pockros PJ, Hamzeh FM, Martin P, et al. Histologic outcomes in hepatitis C-infected patients with varying degrees of virologic response to interferon-based treatments. Hepatol. 2010;52:1193–200.

    Article  CAS  Google Scholar 

  59. Fernandez-Rodriguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105:2164–72. quiz 2173.

    Article  CAS  PubMed  Google Scholar 

  60. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–84.

    Article  PubMed  Google Scholar 

  61. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatol. 2007;45:579–87.

    Article  CAS  Google Scholar 

  62. Van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.

    Article  PubMed  Google Scholar 

  63. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2009;8:280–8. 288 e1.

    Article  PubMed  Google Scholar 

  64. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2009;8:192–9.

    Article  PubMed  Google Scholar 

  65. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27:201–5.

    Article  CAS  PubMed  Google Scholar 

  66. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterol. 2005;128:343–50.

    Article  Google Scholar 

  67. Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatol. 2009;49:1954–61.

    Article  Google Scholar 

  68. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatol. 2010;51:2069–76.

    Article  CAS  Google Scholar 

  69. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatol. 2013;59:1293–302.

    Article  Google Scholar 

  70. Aleman S, Rahbin N, Weiland O, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.

    Article  CAS  PubMed  Google Scholar 

  71. EASL Recommendations on Treatment of Hepatitis C 2014. J Hepatol 2014;S0168-8278:00309–2.

  72. Schinazi R et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34 Suppl 1:69–78.

    Article  CAS  PubMed  Google Scholar 

  73. Estrabaud et al. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol. 2012;57:1110–25.

    Article  CAS  PubMed  Google Scholar 

  74. Codes et al. Gut. 2007;56(3):390–5.

    Article  PubMed Central  PubMed  Google Scholar 

  75. Maylin et al. Gastroenterology. 2008;135(3):821–9.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Julien Vergniol and Victor deLedinghen declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Author information

Authors and Affiliations

  1. Centre d’Investigation de la Fibrose hépatique, Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France

    Julien Vergniol & V. de Lédinghen

  2. INSERM U1053, Université de Bordeaux, Bordeaux, France

    V. de Lédinghen

  3. Centre d’Investigation de la Fibrose hépatique, Service d’Hépato-Gastroentérologie, Hôpital Haut-Lévêque, 33604, Pessac, France

    Julien Vergniol & V. de Lédinghen

Authors
  1. Julien Vergniol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. de Lédinghen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Julien Vergniol or V. de Lédinghen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vergniol, J., de Lédinghen, V. HCV: Fibrosis Progression. Curr Hepatology Rep 13, 265–272 (2014). https://doi.org/10.1007/s11901-014-0247-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-014-0247-1

Keywords

Search

Navigation